Search

Displaying results 7911 - 7920 of 10000 in total
  1. Drug

    Zibotentan

    go.drugbank.com/drugs/DB06629
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

    Synonyms: 4-AP, 4-AminopyridineCategories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates
  4. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®

    Products: PROLIA®, XGEVA® 120 MG/1.7 ML
  5. Drug

    DiaPep 277

    go.drugbank.com/drugs/DB06651
    Investigational

    DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).

    Categories: Group I Chaperonins, Diabetes Mellitus, Type 1
  6. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  7. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

    Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitors
  8. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Clazosentan

    go.drugbank.com/drugs/DB06677
    Investigational

    Categories: Receptor, Endothelin A, Heterocyclic Compounds, 1-Ring
  10. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

    Synonyms: 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracil, L-FMAUCategories: Heterocyclic Compounds, 1-Ring